Fluoroquinolone antibiotics – what we shouldn’t forget two years after the restriction by the European Commission

Kathrin Bausch; Gernot Bonkat

doi:10.4414/SMW.2022.w30126

Viewpoint

Vol. 152 No. 0304 (2022)

Fluoroquinolone antibiotics – what we shouldn’t forget two years after the restriction by the European Commission

Kathrin Bausch
Gernot Bonkat

Cite this as:: Swiss Med Wkly. 2022;152:w30126
Published: 27.01.2022

References

Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Köves B, et al. Guidelines on Urological Infections 2021.
Plate A, Kronenberg A, Risch M, Mueller Y, Di Gangi S, Rosemann T, et al. Treatment of urinary tract infections in Swiss primary care: quality and determinants of antibiotic prescribing. BMC Fam Pract. 2020 Jul;21(1):125. https://doi.org/10.1186/s12875-020-01201-1
Bausch K, Roth JA, Seifert HH, Widmer AF. Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate. Swiss Med Wkly. 2018 Feb;148:w14594. https://doi.org/10.4414/smw.2018.14594
Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019 Oct;75(10):1431–43. https://doi.org/10.1007/s00228-019-02713-1
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.
Swissmedic. Systemisch angewendete Fluorochinolone: Wichtige Anwendungseinschränkungen aufgrund des Sicherheitsprofiles.
Bonkat G, Wagenlehner F. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Eur Urol. 2019 Feb;75(2):205–7. https://doi.org/10.1016/j.eururo.2018.10.057
Kantonsapothekenvereinigung. Empfehlungen zum Off lable use von Medikamenten 2016.
Federal Office of Public Health and Federal Food Safety and Veterinary Office. Swiss Antibiotic Resistance Report 2020. Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland. November 2020. FOPH publication number: 2020-OEG-64. https://www.blv.admin.ch
Piraux A, Faure S, Naber KG, Alidjanov JF, Ramond-Roquin A. Changes in the management of urinary tract infections in women: impact of the new recommendations on antibiotic prescribing behavior in France, between 2014 and 2019. BMC Health Serv Res. 2021 Jun;21(1):612. https://doi.org/10.1186/s12913-021-06653-4
Nunzio CD, Nacchia A, Lombardo R, Franco A, Tema G, Baldassarri V, et al. P0149 Adverse events in patients treated with quinolones and fluoroquinolones before and after European Medicines Agency warning. Eur Urol. 2021;79:S215–6. https://doi.org/10.1016/s0302-2838(21)00540-6 https://doi.org/10.1016/S0302-2838(21)00540-6

How to Cite

1.

Fluoroquinolone antibiotics – what we shouldn’t forget two years after the restriction by the European Commission. Swiss Med Wkly [Internet]. 2022 Jan. 27 [cited 2025 Oct. 18];152(0304):w30126. Available from: https://smw.ch/index.php/smw/article/view/3149

Share

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

DOI:: https://doi.org/10.4414/SMW.2022.w30126

[1] Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Köves B, et al. Guidelines on Urological Infections 2021.

[2] Plate A, Kronenberg A, Risch M, Mueller Y, Di Gangi S, Rosemann T, et al. Treatment of urinary tract infections in Swiss primary care: quality and determinants of antibiotic prescribing. BMC Fam Pract. 2020 Jul;21(1):125. https://doi.org/10.1186/s12875-020-01201-1

[3] Bausch K, Roth JA, Seifert HH, Widmer AF. Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate. Swiss Med Wkly. 2018 Feb;148:w14594. https://doi.org/10.4414/smw.2018.14594

[4] Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019 Oct;75(10):1431–43. https://doi.org/10.1007/s00228-019-02713-1

[5] European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.

[6] Swissmedic. Systemisch angewendete Fluorochinolone: Wichtige Anwendungseinschränkungen aufgrund des Sicherheitsprofiles.

[7] Bonkat G, Wagenlehner F. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Eur Urol. 2019 Feb;75(2):205–7. https://doi.org/10.1016/j.eururo.2018.10.057

[8] Kantonsapothekenvereinigung. Empfehlungen zum Off lable use von Medikamenten 2016.

[9] Federal Office of Public Health and Federal Food Safety and Veterinary Office. Swiss Antibiotic Resistance Report 2020. Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland. November 2020. FOPH publication number: 2020-OEG-64. https://www.blv.admin.ch

[10] Piraux A, Faure S, Naber KG, Alidjanov JF, Ramond-Roquin A. Changes in the management of urinary tract infections in women: impact of the new recommendations on antibiotic prescribing behavior in France, between 2014 and 2019. BMC Health Serv Res. 2021 Jun;21(1):612. https://doi.org/10.1186/s12913-021-06653-4

[11] Nunzio CD, Nacchia A, Lombardo R, Franco A, Tema G, Baldassarri V, et al. P0149 Adverse events in patients treated with quinolones and fluoroquinolones before and after European Medicines Agency warning. Eur Urol. 2021;79:S215–6. https://doi.org/10.1016/s0302-2838(21)00540-6 https://doi.org/10.1016/S0302-2838(21)00540-6